Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M, You R, Liu YP, Zhang YN, Zhang HJ, Zou X, Yang Q, Li CF, Hua YJ, Yu T, Cao JY, Li JB, Mo HY, Guo L, Lin AH, Sun Y, Qian CN, Ma J, Mai HQ, Chen MY. Lin M, et al. Among authors: chen my. Oral Oncol. 2018 May;80:1-8. doi: 10.1016/j.oraloncology.2018.03.002. Epub 2018 Mar 13. Oral Oncol. 2018. PMID: 29706183
The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial.
Yang Q, Xia L, Lin M, Zhang MX, Duan CY, Liu YP, Xie YL, Wang ZQ, You R, Zou X, Hua YJ, Huang PY, Sun R, Hong MH, Chen MY. Yang Q, et al. Among authors: chen my. Oral Oncol. 2021 Oct;121:105494. doi: 10.1016/j.oraloncology.2021.105494. Epub 2021 Aug 20. Oral Oncol. 2021. PMID: 34425533 Clinical Trial.
Efficacy of local therapy to metastatic foci in nasopharyngeal carcinoma: large-cohort strictly-matched retrospective study.
Zhang MX, Liu T, You R, Zou X, Liu YL, Ding X, Duan CY, Xu HS, Liu YP, Jiang R, Wang ZQ, Lin C, Xie YL, Chen SY, Ouyang YF, Xie RQ, Hua YJ, Sun R, Huang PY, Wang SL, Chen MY. Zhang MX, et al. Among authors: chen sy, chen my. Ther Adv Med Oncol. 2022 Jul 15;14:17588359221112486. doi: 10.1177/17588359221112486. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35860835 Free PMC article.
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, Peng L, Liu YP, Duan CY, Yang Q, Lin C, Xie YL, Chen SY, Liu YL, Gu CM, Xie RQ, Huang PY, Hong MH, Hua YJ, Chen MY. Ding X, et al. Among authors: chen sy, chen my. J Clin Oncol. 2023 May 10;41(14):2571-2582. doi: 10.1200/JCO.22.01450. Epub 2023 Feb 3. J Clin Oncol. 2023. PMID: 36735896 Free PMC article. Clinical Trial.
Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R, Sun R, Hua YJ, Li CF, Li JB, Zou X, Yang Q, Liu YP, Zhang YN, Yu T, Cao JY, Zhang MX, Jiang R, Mo HY, Guo L, Cao KJ, Lin AH, Qian CN, Sun Y, Ma J, Chen MY. You R, et al. Among authors: chen my. Int J Cancer. 2017 Sep 15;141(6):1265-1276. doi: 10.1002/ijc.30819. Epub 2017 Jun 23. Int J Cancer. 2017. PMID: 28577306
Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up.
You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, Li CF, Zou X, Yu T, Cao JY, Zhang MX, Jiang R, Sun R, Mo HY, Guo L, Cao KJ, Lin AH, Sun Y, Qian CN, Ma J, Chen MY. You R, et al. Among authors: chen my. Theranostics. 2017 Jun 1;7(8):2314-2324. doi: 10.7150/thno.19710. eCollection 2017. Theranostics. 2017. PMID: 28740554 Free PMC article.
2,228 results